Fig. 8 | Scientific Reports

Fig. 8

From: RNA-seq and bulk RNA-seq data analysis of cancer-related fibroblasts (CAF) in LUAD to construct a CAF-based risk signature

Fig. 8

Response of risk score to PD-L1 blockade immunotherapy in IMvigor210 cohort. (A) Risk score differences between immunotherapy response groups in the IMvigor210 cohort; (B) Immunotherapy response distribution among risk score groups in the IMvigor210 cohort; (C) OS differences among risk score groups in the IMvigor210 cohort; (D) PFS differences between risk score groups in the IMvigor210 cohort; (E-F) Distribution of immunotherapy responses among risk score groups in the GSE78220 cohort. (G) OS differences between risk score groups in advanced patients in the GSE78220; (H) PFS differences in risk score groups in the GSE78220 cohort. *P < 0.05; ****P < 0.0001.

Back to article page